298 related articles for article (PubMed ID: 19402094)
1. PTEN genomic deletion is associated with p-Akt and AR signalling in poorer outcome, hormone refractory prostate cancer.
Sircar K; Yoshimoto M; Monzon FA; Koumakpayi IH; Katz RL; Khanna A; Alvarez K; Chen G; Darnel AD; Aprikian AG; Saad F; Bismar TA; Squire JA
J Pathol; 2009 Aug; 218(4):505-13. PubMed ID: 19402094
[TBL] [Abstract][Full Text] [Related]
2. Genomic deletion of PTEN is associated with tumor progression and early PSA recurrence in ERG fusion-positive and fusion-negative prostate cancer.
Krohn A; Diedler T; Burkhardt L; Mayer PS; De Silva C; Meyer-Kornblum M; Kötschau D; Tennstedt P; Huang J; Gerhäuser C; Mader M; Kurtz S; Sirma H; Saad F; Steuber T; Graefen M; Plass C; Sauter G; Simon R; Minner S; Schlomm T
Am J Pathol; 2012 Aug; 181(2):401-12. PubMed ID: 22705054
[TBL] [Abstract][Full Text] [Related]
3. Resveratrol regulates the PTEN/AKT pathway through androgen receptor-dependent and -independent mechanisms in prostate cancer cell lines.
Wang Y; Romigh T; He X; Orloff MS; Silverman RH; Heston WD; Eng C
Hum Mol Genet; 2010 Nov; 19(22):4319-29. PubMed ID: 20729295
[TBL] [Abstract][Full Text] [Related]
4. PTEN genomic deletion predicts prostate cancer recurrence and is associated with low AR expression and transcriptional activity.
Choucair K; Ejdelman J; Brimo F; Aprikian A; Chevalier S; Lapointe J
BMC Cancer; 2012 Nov; 12():543. PubMed ID: 23171135
[TBL] [Abstract][Full Text] [Related]
5. The PTEN gene in locally progressive prostate cancer is preferentially inactivated by bi-allelic gene deletion.
Verhagen PC; van Duijn PW; Hermans KG; Looijenga LH; van Gurp RJ; Stoop H; van der Kwast TH; Trapman J
J Pathol; 2006 Apr; 208(5):699-707. PubMed ID: 16402365
[TBL] [Abstract][Full Text] [Related]
6. PTEN genomic deletions that characterize aggressive prostate cancer originate close to segmental duplications.
Yoshimoto M; Ludkovski O; DeGrace D; Williams JL; Evans A; Sircar K; Bismar TA; Nuin P; Squire JA
Genes Chromosomes Cancer; 2012 Feb; 51(2):149-60. PubMed ID: 22045666
[TBL] [Abstract][Full Text] [Related]
7. FISH analysis of 107 prostate cancers shows that PTEN genomic deletion is associated with poor clinical outcome.
Yoshimoto M; Cunha IW; Coudry RA; Fonseca FP; Torres CH; Soares FA; Squire JA
Br J Cancer; 2007 Sep; 97(5):678-85. PubMed ID: 17700571
[TBL] [Abstract][Full Text] [Related]
8. Dual inhibition of AKT-mTOR and AR signaling by targeting HDAC3 in
Yan Y; An J; Yang Y; Wu D; Bai Y; Cao W; Ma L; Chen J; Yu Z; He Y; Jin X; Pan Y; Ma T; Wang S; Hou X; Weroha SJ; Karnes RJ; Zhang J; Westendorf JJ; Wang L; Chen Y; Xu W; Zhu R; Wang D; Huang H
EMBO Mol Med; 2018 Apr; 10(4):. PubMed ID: 29523594
[TBL] [Abstract][Full Text] [Related]
9. Is PTEN loss associated with clinical outcome measures in human prostate cancer?
McCall P; Witton CJ; Grimsley S; Nielsen KV; Edwards J
Br J Cancer; 2008 Oct; 99(8):1296-301. PubMed ID: 18854827
[TBL] [Abstract][Full Text] [Related]
10. Cytosolic phospholipase A2α sustains pAKT, pERK and AR levels in PTEN-null/mutated prostate cancer cells.
Hua S; Yao M; Vignarajan S; Witting P; Hejazi L; Gong Z; Teng Y; Niknami M; Assinder S; Richardson D; Dong Q
Biochim Biophys Acta; 2013 Jun; 1831(6):1146-57. PubMed ID: 23500889
[TBL] [Abstract][Full Text] [Related]
11. PTEN genomic deletion is an early event associated with ERG gene rearrangements in prostate cancer.
Bismar TA; Yoshimoto M; Vollmer RT; Duan Q; Firszt M; Corcos J; Squire JA
BJU Int; 2011 Feb; 107(3):477-85. PubMed ID: 20590547
[TBL] [Abstract][Full Text] [Related]
12. Interplay Among PI3K/AKT, PTEN/FOXO and AR Signaling in Prostate Cancer.
Yan Y; Huang H
Adv Exp Med Biol; 2019; 1210():319-331. PubMed ID: 31900915
[TBL] [Abstract][Full Text] [Related]
13. Klf5 deletion promotes Pten deletion-initiated luminal-type mouse prostate tumors through multiple oncogenic signaling pathways.
Xing C; Ci X; Sun X; Fu X; Zhang Z; Dong EN; Hao ZZ; Dong JT
Neoplasia; 2014 Nov; 16(11):883-99. PubMed ID: 25425963
[TBL] [Abstract][Full Text] [Related]
14. Analytic validation of a clinical-grade PTEN immunohistochemistry assay in prostate cancer by comparison with PTEN FISH.
Lotan TL; Wei W; Ludkovski O; Morais CL; Guedes LB; Jamaspishvili T; Lopez K; Hawley ST; Feng Z; Fazli L; Hurtado-Coll A; McKenney JK; Simko J; Carroll PR; Gleave M; Lin DW; Nelson PS; Thompson IM; True LD; Brooks JD; Lance R; Troyer D; Squire JA
Mod Pathol; 2016 Aug; 29(8):904-14. PubMed ID: 27174589
[TBL] [Abstract][Full Text] [Related]
15. Amplification of the androgen receptor gene in bone metastases from hormone-refractory prostate cancer.
Brown RS; Edwards J; Dogan A; Payne H; Harland SJ; Bartlett JM; Masters JR
J Pathol; 2002 Oct; 198(2):237-44. PubMed ID: 12237884
[TBL] [Abstract][Full Text] [Related]
16. Interfocal heterogeneity of PTEN/MMAC1 gene alterations in multiple metastatic prostate cancer tissues.
Suzuki H; Freije D; Nusskern DR; Okami K; Cairns P; Sidransky D; Isaacs WB; Bova GS
Cancer Res; 1998 Jan; 58(2):204-9. PubMed ID: 9443392
[TBL] [Abstract][Full Text] [Related]
17. Liposome encapsulation of curcumin and resveratrol in combination reduces prostate cancer incidence in PTEN knockout mice.
Narayanan NK; Nargi D; Randolph C; Narayanan BA
Int J Cancer; 2009 Jul; 125(1):1-8. PubMed ID: 19326431
[TBL] [Abstract][Full Text] [Related]
18. Differential regulation of PTEN expression by androgen receptor in prostate and breast cancers.
Wang Y; Romigh T; He X; Tan MH; Orloff MS; Silverman RH; Heston WD; Eng C
Oncogene; 2011 Oct; 30(42):4327-38. PubMed ID: 21532617
[TBL] [Abstract][Full Text] [Related]
19. Interphase FISH analysis of PTEN in histologic sections shows genomic deletions in 68% of primary prostate cancer and 23% of high-grade prostatic intra-epithelial neoplasias.
Yoshimoto M; Cutz JC; Nuin PA; Joshua AM; Bayani J; Evans AJ; Zielenska M; Squire JA
Cancer Genet Cytogenet; 2006 Sep; 169(2):128-37. PubMed ID: 16938570
[TBL] [Abstract][Full Text] [Related]
20. RUNX2 overexpression and PTEN haploinsufficiency cooperate to promote CXCR7 expression and cellular trafficking, AKT hyperactivation and prostate tumorigenesis.
Bai Y; Yang Y; Yan Y; Zhong J; Blee AM; Pan Y; Ma T; Karnes RJ; Jimenez R; Xu W; Huang H
Theranostics; 2019; 9(12):3459-3475. PubMed ID: 31281490
[No Abstract] [Full Text] [Related]
[Next] [New Search]